LDN-212854
SIGMA/SML0965 - ≥98% (HPLC)
Synonym: 5-
CAS Number: 1432597-26-6
Empirical Formula (Hill Notation): C25H22N6
Molecular Weight: 406.48
Linear Formula: C25H22N6
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C25H22N6/c1-3-21(22-4- |
| InChI key | BBDGBGOVJPEFBT-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | [n]21ncc(c2ncc(c1)c5ccc(c |
| solubility | DMSO: 1 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | LDN-212854 is a selective and potent inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases with over 5,000-fold selectivity for BMP versus the closely related TGF-β and activin type I receptors. LDN-212854 has some selectivity for ALK2 with an IC50 of 1.3 nM in preference to other BMP type I receptors, ALK1 (IC50=2.4 nM) and ALK3 (IC50=85.8 nM). LDN-212854 shows better selectivity than LDN193189 in cell-based assays of BMP signaling. LDN-212854 inhibited BMP6-induced osteogenic differentiation, which functions primarily via ALK2, more potently than BMP4, which functions primarily with ALK3 (IC50s of 10 nM versus 40.5 nM), whereas LDN-193189 inhibited both equally. The only off target effects found against a panel of 198 kinases were for RIPK2, ABL1, and PDGFR-β with IC50 values < 100 nM. |
| Biochem/physiol Actions: | LDN-212854 is a selective and potent inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases. |
| Biochem/physiol Actions: | LDN-212854 is also known as 5-[6-[4-(1-Piperazinyl)ph |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |

